Patent · US Active

Substituted quinazolines as HDAC6 inhibitors

US12421222B2 · kind B2 · utility

0Cited by

0References

29Claims

0Family size

Assignee

AUGUSTINE THERAPEUTICS · BE

Inventors

Sylvain Celanire · Geneva, CH
Joao Fernando DOS SANTOS CARVALHO · Heverlee, BE
Frederik Jan Rita Rombouts · Wilrijk, BE
Peter Sennhenn · Munich, DE
Michele CURCIO · Egenhoven, BE
Joana Catarina REIS PEDRO · Egenhoven, BE

Key dates

Filing date	Jan 10, 2025
Grant date	Sep 23, 2025
Priority date	—
Expiry date	Jan 10, 2045

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.